AD/PD 2025: Cerevance's Solengepras falls short of primary endpoint in ASCEND trial
At the AD/PD 2025 Conference, Cerevance revealed that solengepras didn't meet its primary endpoint in the Phase II ASCEND trial for early Parkinson's disease. The drug showed potential benefits in non-motor symptoms despite missing statistical significance.